Market Overview

Insmed Up Over 30% Following FDA Decision

Related INSM
Watch These 5 Huge Put Purchases In Tuesday Trade
Benzinga's Option Alert Recap From February 6
Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers (Seeking Alpha)

Insmed (NASDAQ: INSM) shareholders are having a big day. Shares are up over 33 percent after the company announced that the FDA granted Arikayce breakthrough therapy designation.

Arikayce is designed to treat lung infections; more specifically, nontuberculous mycobacterial lung disease.

Insmed further stated that the designation was based on results from the phase two trial and the company plans to meet with the FDA to form a regulation pathway.

Shares were last trading at $16.65, a 33.57 percent gain.

Posted-In: News FDA


Related Articles (INSM)

View Comments and Join the Discussion!